Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh.

Bangladesh Cholera Cost Vaccine

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 13 06 2022
revised: 01 12 2022
accepted: 02 12 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 23 12 2022
Statut: epublish

Résumé

Cholera poses a substantial health burden in the developing world due to both epidemic and endemic diseases. The World Health Organization recommends oral cholera vaccines for mass vaccination campaigns in addition to traditional prevention practices and treatments in resource-poor settings. In many developing countries like Bangladesh, the major challenge behind implementing mass vaccination campaigns concerns the affordability of the oral cholera vaccine (OCV). Vaccination of children with OCV is not only an impactful approach for controlling cholera at the population level and reducing childhood morbidity but is also considered more cost-effective than vaccinating all ages. The aim of the study was to estimate the cost of an OCV campaign for children from a societal perspective using empirical study. A total of 66,311 children aged 1 to 14 years old were fully vaccinated with two doses of the OCV Shanchol while 9,035 individuals received one dose of this vaccine. The estimated societal cost per individual for full vaccination was US$ 6.11, which includes the cost of vaccine delivery estimated at US$ 1.95. The cost per single dose was estimated at US$ 2.86. The total provider cost for full vaccination was estimated at US$ 6.01 and the recipient cost at US$ 0.10. Our estimation of OCV delivery costs for children was relatively higher than what was found in a similar mass OCV campaign for all age groups, indicating that there may be additional cost factors to consider in targeted vaccine campaigns. This analysis provides useful benchmarks for the possible costs related to delivery of OCV to children and future OCV cost-effectiveness models should factor in these possible cost disparities. Attempts to reduce the cost per dose are likely to have a greater impact on the cost of similar vaccination campaigns in many resource-poor settings.

Identifiants

pubmed: 36545347
doi: 10.1016/j.jvacx.2022.100247
pii: S2590-1362(22)00107-3
pmc: PMC9761845
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100247

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS Negl Trop Dis. 2015 Sep 09;9(9):e0004072
pubmed: 26352143
Vaccine. 2020 Feb 29;38 Suppl 1:A127-A131
pubmed: 31301917
Vaccine. 2008 Nov 25;26(50):6305-16
pubmed: 18835415
Lancet. 1986 Jul 19;2(8499):124-7
pubmed: 2873397
Vaccine. 2015 Sep 11;33(38):4916-21
pubmed: 26232545
Clin Infect Dis. 2020 Oct 23;71(7):1635-1642
pubmed: 31891368
Health Policy Plan. 2015 Mar;30 Suppl 1:i32-45
pubmed: 25759453
Vaccine. 2015 Dec 16;33(51):7357-7363
pubmed: 26519548
PLoS Negl Trop Dis. 2016 Dec 8;10(12):e0005124
pubmed: 27930668
Lancet. 2015 Oct 3;386(10001):1362-1371
pubmed: 26164097
Hum Vaccin Immunother. 2018;14(10):2427-2433
pubmed: 29648523
Value Health. 2009 Sep;12(6):899-908
pubmed: 19824189
PLoS Negl Trop Dis. 2014 Dec 04;8(12):e3343
pubmed: 25473851
Lancet Infect Dis. 2017 Oct;17(10):1080-1088
pubmed: 28729167
PLoS Negl Trop Dis. 2018 Oct 9;12(10):e0006652
pubmed: 30300420
BMC Infect Dis. 2017 Dec 19;17(1):779
pubmed: 29258447
Hum Vaccin Immunother. 2019;15(6):1294-1301
pubmed: 30183486
Vaccine. 2006 May 29;24(22):4890-5
pubmed: 16298025
Ther Adv Infect Dis. 2018 Jan;5(1):29-43
pubmed: 29344358
Lancet Infect Dis. 2021 Oct;21(10):1407-1414
pubmed: 34146473
Lancet Infect Dis. 2013 Dec;13(12):1050-6
pubmed: 24140390
Am J Trop Med Hyg. 2014 Dec;91(6):1181-1189
pubmed: 25294614
Am J Trop Med Hyg. 2017 Oct;97(4_Suppl):37-42
pubmed: 29064362
PLoS Negl Trop Dis. 2015 Jun 04;9(6):e0003832
pubmed: 26043000
Vaccine. 2021 Jan 3;39(1):121-124
pubmed: 33303179
Vaccine. 2001 Jun 14;19(27):3720-5
pubmed: 11395206

Auteurs

Abdur Razzaque Sarker (AR)

Population Studies Division, Bangladesh Institute of Development Studies (BIDS), Bangladesh.
Health Economics Unit, University of Birmingham, Birmingham, United Kingdom.

Ashraful Islam Khan (AI)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Md Taufiqul Islam (MT)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Fahima Chowdhury (F)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Farhana Khanam (F)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Sophie Kang (S)

International Vaccine Institute, Seoul, Republic of Korea.

Faisal Ahmmed (F)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Justin Im (J)

International Vaccine Institute, Seoul, Republic of Korea.

Deok Ryun Kim (DR)

International Vaccine Institute, Seoul, Republic of Korea.

Birkneh Tilahun Tadesse (BT)

International Vaccine Institute, Seoul, Republic of Korea.
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden.
Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia.

Tasnuva Ahmed (T)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Asma Binte Aziz (AB)

International Vaccine Institute, Seoul, Republic of Korea.

Masuma Hoque (M)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Juyeon Park (J)

International Vaccine Institute, Seoul, Republic of Korea.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, United Kingdom.

Xinxue Liu (X)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, United Kingdom.

Gideok Pak (G)

International Vaccine Institute, Seoul, Republic of Korea.

Khalequ Zaman (K)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Florian Marks (F)

International Vaccine Institute, Seoul, Republic of Korea.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, United Kingdom.
University of Antananarivo, Antananarivo, Madagascar.
Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.

Jerome H Kim (JH)

International Vaccine Institute, Seoul, Republic of Korea.

John D Clemens (JD)

International Vaccine Institute, Seoul, Republic of Korea.
UCLA Fielding School of Public Health, Los Angeles, CA 90095-1772, USA.

Firdausi Qadri (F)

International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Classifications MeSH